Bristol Myers Squibb (BMY) announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl (luspatercept-aamt) versus placebo for anemia in adults with Alpha (β)-Thalassemia.
Importance
Level 1
- "The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with β‑thalassemia, and a statistically significant and clinically meaningful decrease in red blood cell (RBC) transfusion burden in TD patients with β‑thalassemia.
- The study also met all key secondary endpoints.
- Safety findings were consistent with the known profile of Reblozyl in thalassemia.
#BRISTOL-MYERS SQUIBB CO#BMY.US#REGAL-BELOIT CORP#RBC.US#TORONTO-DOMINION BANK/THE#TD.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES